{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T12:35:52Z","timestamp":1764333352127,"version":"3.46.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T00:00:00Z","timestamp":1764288000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T00:00:00Z","timestamp":1764288000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Novartis"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"DOI":"10.1186\/s12883-025-04343-w","type":"journal-article","created":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T12:24:54Z","timestamp":1764332694000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A real-world retrospective study to assess the effectiveness and safety profile of siponimod in Chinese patients with relapsing forms of multiple sclerosis"],"prefix":"10.1186","volume":"25","author":[{"given":"Yao","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongbo","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zheng","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Cai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lyra","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,28]]},"reference":[{"issue":"3","key":"4343_CR1","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1097\/wco.0000000000000094","volume":"27","author":"R Dutta","year":"2014","unstructured":"Dutta R, Trapp BD. Relapsing and progressive forms of multiple sclerosis: insights from pathology. Curr Opin Neurol. 2014;27(3):271\u20138. https:\/\/doi.org\/10.1097\/wco.0000000000000094.","journal-title":"Curr Opin Neurol"},{"issue":"Suppl 1","key":"4343_CR2","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.5152\/npa.2015.12608","volume":"52","author":"H Efendi","year":"2015","unstructured":"Efendi H. Clinically isolated syndromes: clinical characteristics, differential diagnosis, and management. Noro Psikiyatr Ars. 2015;52(Suppl 1):S1\u201311. https:\/\/doi.org\/10.5152\/npa.2015.12608.","journal-title":"Noro Psikiyatr Ars"},{"key":"4343_CR3","doi-asserted-by":"publisher","first-page":"100010","DOI":"10.1016\/j.lanwpc.2020.100010","volume":"1","author":"DC Tian","year":"2020","unstructured":"Tian DC, Zhang C, Yuan M, Yang X, Gu H, Li Z, et al. Incidence of multiple sclerosis in china: a nationwide hospital-based study. Lancet Reg Health West Pac. 2020;1:100010. https:\/\/doi.org\/10.1016\/j.lanwpc.2020.100010.","journal-title":"Lancet Reg Health West Pac"},{"issue":"10","key":"4343_CR4","doi-asserted-by":"publisher","first-page":"5382","DOI":"10.1007\/s00415-022-11193-w","volume":"269","author":"M Filippi","year":"2022","unstructured":"Filippi M, Amato MP, Centonze D, Gallo P, Gasperini C, Inglese M, et al. Early use of high-efficacy disease\u2013modifying therapies makes the difference in people with multiple sclerosis: an expert opinion. J Neurol. 2022;269(10):5382\u201394. https:\/\/doi.org\/10.1007\/s00415-022-11193-w.","journal-title":"J Neurol"},{"key":"4343_CR5","doi-asserted-by":"publisher","first-page":"175628642412391","DOI":"10.1177\/17562864241239117","volume":"17","author":"J Guo","year":"2024","unstructured":"Guo J, Wu J, Wang L, Liu H, Wu X, Yang H, et al. Treatment algorithms of relapsing multiple sclerosis: an exploration based on the available disease-modifying therapies in China. Ther Adv Neurol Disord. 2024;17:17562864241239117. https:\/\/doi.org\/10.1177\/17562864241239117.","journal-title":"Ther Adv Neurol Disord"},{"issue":"4","key":"4343_CR6","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1080\/14656566.2023.2178898","volume":"24","author":"L Dumitrescua","year":"2023","unstructured":"Dumitrescua L, Papathanasiou A, Coclitu C, Garjani A, Evangelou N, Constantinescu CS, et al. An update on the use of sphingosine 1-phosphate receptor modulators for the treatment of relapsing multiple sclerosis. Expert Opin Pharmacotherapy. 2023;24(4):495\u2013509. https:\/\/doi.org\/10.1080\/14656566.2023.2178898.","journal-title":"Expert Opin Pharmacotherapy"},{"issue":"4","key":"4343_CR7","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s40268-023-00434-6","volume":"23","author":"M Vali\u0161","year":"2023","unstructured":"Vali\u0161 M, Achiron A, Hartung HP, Mare\u0161 J, Tich\u00e1 V, \u0160toura\u010d P, et al. The benefits and risks of switching from fingolimod to siponimod for the treatment of relapsing\u2013remitting and secondary progressive multiple sclerosis. Drugs R D. 2023;23(4):331\u201338. https:\/\/doi.org\/10.1007\/s40268-023-00434-6","journal-title":"Drugs R D"},{"issue":"8","key":"4343_CR8","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1016\/s1474-4422(13)70102-9","volume":"12","author":"K Selmaj","year":"2013","unstructured":"Selmaj K, Li DK, Hartung HP, Hemmer B, Kappos L, Freedman MS, et al. Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study. Lancet Neurol. 2013;12(8):756\u201367. https:\/\/doi.org\/10.1016\/s1474-4422(13)70102-9.","journal-title":"Lancet Neurol"},{"key":"4343_CR9","unstructured":"Novartis. Novartis receives FDA approval for Mayzent\u00ae (siponimod), the first oral drug to treat secondary progressive MS with active disease. 2019 https:\/\/www.novartis.com\/news\/media-releases\/novartis-receives-fda-approval-mayzent-siponimod-first-oral-drug-treat-secondary-progressive-ms-active-disease#:~:text=Basel%2C%20March%2027%2C%202019%20%2D,disease%2C%20relapsing%20remitting%20multiple%20sclerosis\/. Accessed 27 January 2025."},{"issue":"9","key":"4343_CR10","doi-asserted-by":"publisher","first-page":"5093","DOI":"10.1007\/s00415-022-11166-z","volume":"269","author":"R Gold","year":"2022","unstructured":"Gold R, Piani-Meier D, Kappos L, Bar-Or A, Vermersch P, Giovannoni G, et al. Siponimod vs placebo in active secondary progressive multiple sclerosis: a post hoc analysis from the phase 3 EXPAND study. J Neurol. 2022;269(9):5093\u2013104. https:\/\/doi.org\/10.1007\/s00415-022-11166-z.","journal-title":"J Neurol"},{"key":"4343_CR11","unstructured":"National Medical Products Administration. Approval of siponimod by China National Medical Products Administration. 2022. https:\/\/www.nmpa.gov.cn\/directory\/web\/nmpa\/yaowen\/ypjgyw\/20200511091401189.html Accessed 27 January 2025."},{"key":"4343_CR12","unstructured":"Australian Government. Department of Health and Aged Care. Medical Dictionary for Regulatory Activities. 2016. Medical dictionary for regulatory Activities - MedDRA | therapeutic goods administration (TGA). https:\/\/www.tga.gov.au\/safety\/database-adverse-event-notifications-daen\/tips-searching-daen-medicines\/medical-dictionary-regulatory-activities-meddra . Accessed 4 April 2025."},{"issue":"Suppl 1","key":"4343_CR13","doi-asserted-by":"publisher","first-page":"S69","DOI":"10.29399\/npa.23343","volume":"55","author":"BP \u00c7inar","year":"2018","unstructured":"\u00c7inar BP, Yorgun YG. What we learned from the history of multiple sclerosis measurement: Expanded Disability Status Scale. Noro Psikiyatr Ars. 2018;55(Suppl 1):S69\u201375. https:\/\/doi.org\/10.29399\/npa.23343","journal-title":"Noro Psikiyatr Ars"},{"key":"4343_CR14","doi-asserted-by":"publisher","first-page":"102461","DOI":"10.1016\/j.msard.2020.102461","volume":"46","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, Xu Y, Xu T, Yin H, Zhu Y, Peng B, et al. Prediction of long-term disability in Chinese patients with multiple sclerosis: A prospective cohort study. Mult Scler Relat Disord. 2020;46:102461. https:\/\/doi.org\/10.1016\/j.msard.2020.102461.","journal-title":"Mult Scler Relat Disord"},{"issue":"6","key":"4343_CR15","doi-asserted-by":"publisher","first-page":"591","DOI":"10.3988\/jcn.2024.0149","volume":"20","author":"K Stavrogianni","year":"2024","unstructured":"Stavrogianni K, Kitsos DK, Giannopapas V, Stefanou MI, Christouli N, Smyrni V, et al. Impact of siponimod on clinical and radiological parameters of secondary progressive multiple sclerosis: A real-world prospective study. J Clin Neurol. 2024;20(6):591\u20138. https:\/\/doi.org\/10.3988\/jcn.2024.0149","journal-title":"J Clin Neurol"},{"issue":"10127","key":"4343_CR16","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1016\/s0140-6736(18)30475-6","volume":"391","author":"L Kappos","year":"2018","unstructured":"Kappos L, Bar-Or A, Cree BAC, Fox RJ, Giovannoni G, Gold R, et al. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. Lancet. 2018;391(10127):1263\u201373. https:\/\/doi.org\/10.1016\/s0140-6736(18)30475-6.","journal-title":"Lancet"},{"issue":"1","key":"4343_CR17","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s42466-022-00219-3","volume":"4","author":"L Regner-Nelke","year":"2022","unstructured":"Regner-Nelke L, Pawlitzki M, Willison A, Rolfes L, Oezalp SH, Nelke C, et al. Real-world evidence on siponimod treatment in patients with secondary progressive multiple sclerosis. Neurolog Res Pract. 2022;4(1):55. https:\/\/doi.org\/10.1186\/s42466-022-00219-3","journal-title":"Neurolog Res Pract"},{"issue":"10","key":"4343_CR18","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1177\/13524585221083194","volume":"28","author":"BA Cree","year":"2022","unstructured":"Cree BA, Arnold DL, Fox RJ, Gold R, Vermersch P, Benedict RHB, et al. Long-term efficacy and safety of siponimod in patients with secondary progressive multiple sclerosis: analysis of EXPAND core and extension data up to >\u20095 years. Mult Scler. 2022;28(10):1591\u2013605. https:\/\/doi.org\/10.1177\/13524585221083194","journal-title":"Mult Scler"},{"key":"4343_CR19","unstructured":"Novartis. Summary of Product Characteristics: Mayzent\u00ae (siponimod) tablets, for oral use. 2024. https:\/\/www.novartis.com\/us-en\/sites\/novartis_us\/files\/mayzent.pdf. Accessed 27 January 2025."}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-025-04343-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-025-04343-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-025-04343-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T12:24:56Z","timestamp":1764332696000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcneurol.biomedcentral.com\/articles\/10.1186\/s12883-025-04343-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,28]]},"references-count":19,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4343"],"URL":"https:\/\/doi.org\/10.1186\/s12883-025-04343-w","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,28]]},"assertion":[{"value":"3 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki, and ethics approval was received from the Ethical Committee of Peking Union Medical College Hospital on 8 December 2022. All patients signed an Informed Consent Form prior to participation in the study. All data were anonymized prior to entry into the eCRFs. No experiments involving humans or human tissue samples were conducted during the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Lyra Liu, Min Cai, Ming Zhou, and Zheng Li are employees of China Novartis Institutes for Biomedical Research, China. Anne Lin is an employee of IQVIA, China Taiwan. IQVIA has received funding from Novartis for running this study and for medical writing support. Yan Xu, Yao Zhang, and Hongbo Liu have nothing to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"491"}}